AUPH
HEALTHCAREAurinia Pharmaceuticals Inc
$16.25+0.20 (+1.28%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving AUPH Today?
No stock-specific AI insight has been generated for AUPH yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$7.29$16.88
$16.25
Fundamentals
Market Cap$2.1B
P/E Ratio7.9
EPS$2.07
Dividend Yield—
Dividend / Share—
ROE0.6%
Profit Margin1.0%
Debt / Equity—
Trading
Volume715K
Avg Volume (10D)—
Shares Outstanding129.9M
AUPH News
21 articles- Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top EstimatesYahoo Finance·May 7, 2026
- Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business ProgressYahoo Finance·May 7, 2026
- ARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock?Yahoo Finance·Apr 23, 2026
- 7MM Systemic Lupus Erythematosus and Lupus Nephritis Drug Market Analysis & Forecast 2024-2034: Future SLE and LN Players Competition, High Unmet Need for Steroid-sparing TreatmentsGlobeNewswire Inc.·Apr 10, 2026
- United rises on IPF results; Biogen scores positive lupus data and an approvalBiopharmadive·Mar 30, 2026
- Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value RightYahoo Finance·Mar 30, 2026
- Does Aurinia’s Tang‑Led Leadership Overhaul Reshape the Bull Case for Aurinia Pharmaceuticals (AUPH)?Yahoo Finance·Mar 29, 2026
- Mutiny At Aurinia Pharmaceuticals? Biotech Rallies On C-Suite Shake-UpYahoo Finance·Mar 23, 2026
- MKT Capital Applauds Aurinia Pharmaceuticals’ Management TransitionYahoo Finance·Mar 23, 2026
- Aurinia Announces Management TransitionYahoo Finance·Mar 23, 2026
- Evommune Stock Sees RS Rating Rise To 91Yahoo Finance·Mar 18, 2026
- Is Aurinia Pharmaceuticals (AUPH) Pricing Reflect Long Term Value After 71% One Year GainYahoo Finance·Mar 15, 2026
- W.R. Berkley, Ziff Davis, and More Stocks See Action From Activist InvestorsYahoo Finance·Mar 14, 2026
- KalVista Pharmaceuticals Stock Sees RS Rating Jump To 86Yahoo Finance·Mar 11, 2026
- Viking Therapeutics Stock Gets RS Rating UpgradeYahoo Finance·Mar 10, 2026
- Xenon Pharmaceuticals Stock Sees RS Rating Rise To 77Yahoo Finance·Mar 4, 2026
- Should Aurinia’s Surging 2025 Earnings and Upbeat 2026 Outlook Require Action From Aurinia (AUPH) Investors?Yahoo Finance·Mar 3, 2026
- Aurinia Pharmaceuticals (AUPH) Reports Financial Results for Three and Twelve Months Ended December 31, 2025Yahoo Finance·Mar 1, 2026
- Aurinia Pharmaceuticals Inc. Q4 2025 Earnings Call SummaryMoby·Feb 27, 2026
- Aurinia Pharmaceuticals Inc (AUPH) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...Yahoo Finance·Feb 26, 2026
- Aurinia Pharmaceuticals Q4 Earnings Call HighlightsMarketbeat·Feb 26, 2026
All 21 articles loaded
Price Data
Open$16.21
Previous Close$16.04
Day High$16.25
Day Low$16.03
52 Week High$16.88
52 Week Low$7.29
52-Week Range
$7.29$16.88
$16.25
Fundamentals
Market Cap$2.1B
P/E Ratio7.9
EPS$2.07
Dividend Yield—
Dividend / Share—
ROE0.6%
Profit Margin1.0%
Debt / Equity—
Trading
Volume715K
Avg Volume (10D)—
Shares Outstanding129.9M
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—